SCHEMBL7146699

SCHEMBL7146699

Cc1cccc(NS(=O)(=O)CCSc2nc3cc(C)ccc3s2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
HSD17B10 Q99714 1/20 0.47
MAPT P10636 12/20 0.44
LMNA P02545 3/20 0.44
HTT P42858 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KMT2A Q03164 2/20 0.44
THRB P10828 2/20 0.41
HSP90AA1 P07900 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CYP1A2 P05177 4/20 0.40
CYP2C19 P33261 3/20 0.40
IDO1 P14902 1/20 0.40
CYP3A4 P08684 3/20 0.40
CYP2D6 P10635 3/20 0.40
CYP2C9 P11712 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7146167 0.94 ALDH1A1 (0.43) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7148116 0.93 ALDH1A1 (0.42) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7149659 0.91 ALDH1A1 (0.59) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7153409 0.90 LMNA (0.48) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7147361 0.90 ALDH1A1 (0.47) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7153276 0.89 MAPT (0.43) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7147570 0.85 ALDH1A1 (0.54) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7151763 0.85 POLB (0.42) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7147065 0.84 LMNA (0.46) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7148130 0.84 MAPT (0.46) ALDH1A1HSD17B10MAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 ALDH1A1 2919/4885HSD17B10 2088/4885MAPT 3839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.